M3814 is a potent specific inhibitor of DNA-PK (DNA-PKIC50 = 0.0006 μM) currently in clinical trial in combination with chemotherapy for relapsed/refractory AML (NCT03983824). Here, PRKDC is linked to acute myeloid leukemia.